Researchers’ success in using lipid nanoparticles to treat leukemia

Researchers’ success in using lipid nanoparticles to treat leukemia

to report Jam Jam online From the news-medical website, every year, about 13 thousand people in Germany are diagnosed with leukemia. Leukemia refers to different types of blood cancer. Among the people suffering from this disease, there are many children and teenagers under 15 years old.

A common and highly aggressive form of leukemia in adults is acute myeloid leukemia (AML). In this type of disease, blood cells in the early stages – stem cells and progenitor cells – turn into cancer cells. This type of disease is the second most common form of leukemia in children, which accounts for about four percent of all malignant diseases in childhood and adolescence.

According to reports, in acute myeloid leukemia despite treatment with chemotherapy, only between 20 and 50% survive in the first five years after diagnosis and treatment. Half or more relapse and die. In addition, these common treatments have severe side effects: in particular, those that damage blood stem cells. Therefore, there is an urgent need to develop new therapeutic methods suitable for AML acute myeloid leukemia.

Researchers led by Dr. Jan Henning Klossman from the Children’s Department and Dr. Dirk Heckel from the Institute of Pediatric Hematology and Oncology at Goethe University Frankfurt in Germany have recently successfully tested a treatment for leukemia in animals. They used a therapeutic RNA molecule packaged in lipid nanoparticles to treat animals with leukemia.

Klossman explained about this research: By packaging RNA in lipid nanoparticles, we basically used the same method that was used to immunize Corona. Lipid nanoparticles deliver therapeutic RNA into blood cells.

He added: MIR-193B therapeutic RNA was previously introduced in 2018 as a protective effect against cancer. In healthy cells, miR-193b slows down signaling pathways that are activated only for cell proliferation. For this reason, miR-193b is called a tumor suppressor. However, in AML cells, miR-193b is not present in sufficient amounts, so it is unable to perform its task as a tumor suppressor.

This researcher mentioned: All the laboratory animals tolerated the treatment with nanoparticles containing the active substance well, and the leukemia cells were successfully destroyed.

“We were able to increase the survival time in all the animals we treated, and some were even cured,” Klossman also said. What is encouraging is that miR-193b worked in all AML subtypes tested.


This news article has been translated from the original language to English by

You can visit the original source at the link below.

Original Source Link